Role and mechanism of action of sclerostin in bone

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

After discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency or pharmacological neutralization increases bone formation. Dysregulation of sclerostin expression also underlies the pathophysiology of skeletal disorders characterized by loss of bone mass, as well as the damaging effects of some cancers in bone. Thus, sclerostin has quickly become a promising molecular target for the treatment of osteoporosis and other skeletal diseases, and beneficial skeletal outcomes are observed in animal studies and clinical trials using neutralizing antibodies against sclerostin. However, the anabolic effect of blocking sclerostin decreases with time, bone mass accrual is also accompanied by anti-catabolic effects, and there is bone loss over time after therapy discontinuation. Further, the cellular source of sclerostin in the bone/bone marrow microenvironment under physiological and pathological conditions, the pathways that regulate sclerostin expression and the mechanisms by which sclerostin modulates the activity of osteocytes, osteoblasts, and osteoclasts remain unclear. In this review, we highlight the current knowledge on the regulation of Sost/sclerotin expression and its mechanism(s) of action, discuss novel observations regarding its role in signaling pathways activated by hormones and mechanical stimuli in bone, and propose future research needed to understand the full potential of therapeutic interventions that modulate Sost/sclerostin expression.

Original languageEnglish (US)
Pages (from-to)29-37
Number of pages9
JournalBone
Volume96
DOIs
StatePublished - Mar 1 2017

Fingerprint

Bone and Bones
Osteochondrodysplasias
Anabolic Agents
Osteocytes
Bone Neoplasms
Osteoclasts
Neutralizing Antibodies
Osteoblasts
Osteogenesis
Osteoporosis
Homeostasis
Therapeutics
Bone Marrow
Clinical Trials
Hormones
Pharmacology

Keywords

  • Anabolism
  • Bone formation
  • Bone resorption
  • Glucocorticoids
  • Multiple myeloma
  • Osteocytes
  • PTH
  • Wnt/βcatenin signaling

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Histology
  • Physiology

Cite this

Role and mechanism of action of sclerostin in bone. / Delgado-Calle, Jesus; Sato, Amy; Bellido, Teresita.

In: Bone, Vol. 96, 01.03.2017, p. 29-37.

Research output: Contribution to journalArticle

@article{d063cc3da89b4ead987eb170f0b540e1,
title = "Role and mechanism of action of sclerostin in bone",
abstract = "After discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency or pharmacological neutralization increases bone formation. Dysregulation of sclerostin expression also underlies the pathophysiology of skeletal disorders characterized by loss of bone mass, as well as the damaging effects of some cancers in bone. Thus, sclerostin has quickly become a promising molecular target for the treatment of osteoporosis and other skeletal diseases, and beneficial skeletal outcomes are observed in animal studies and clinical trials using neutralizing antibodies against sclerostin. However, the anabolic effect of blocking sclerostin decreases with time, bone mass accrual is also accompanied by anti-catabolic effects, and there is bone loss over time after therapy discontinuation. Further, the cellular source of sclerostin in the bone/bone marrow microenvironment under physiological and pathological conditions, the pathways that regulate sclerostin expression and the mechanisms by which sclerostin modulates the activity of osteocytes, osteoblasts, and osteoclasts remain unclear. In this review, we highlight the current knowledge on the regulation of Sost/sclerotin expression and its mechanism(s) of action, discuss novel observations regarding its role in signaling pathways activated by hormones and mechanical stimuli in bone, and propose future research needed to understand the full potential of therapeutic interventions that modulate Sost/sclerostin expression.",
keywords = "Anabolism, Bone formation, Bone resorption, Glucocorticoids, Multiple myeloma, Osteocytes, PTH, Wnt/βcatenin signaling",
author = "Jesus Delgado-Calle and Amy Sato and Teresita Bellido",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.bone.2016.10.007",
language = "English (US)",
volume = "96",
pages = "29--37",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Role and mechanism of action of sclerostin in bone

AU - Delgado-Calle, Jesus

AU - Sato, Amy

AU - Bellido, Teresita

PY - 2017/3/1

Y1 - 2017/3/1

N2 - After discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency or pharmacological neutralization increases bone formation. Dysregulation of sclerostin expression also underlies the pathophysiology of skeletal disorders characterized by loss of bone mass, as well as the damaging effects of some cancers in bone. Thus, sclerostin has quickly become a promising molecular target for the treatment of osteoporosis and other skeletal diseases, and beneficial skeletal outcomes are observed in animal studies and clinical trials using neutralizing antibodies against sclerostin. However, the anabolic effect of blocking sclerostin decreases with time, bone mass accrual is also accompanied by anti-catabolic effects, and there is bone loss over time after therapy discontinuation. Further, the cellular source of sclerostin in the bone/bone marrow microenvironment under physiological and pathological conditions, the pathways that regulate sclerostin expression and the mechanisms by which sclerostin modulates the activity of osteocytes, osteoblasts, and osteoclasts remain unclear. In this review, we highlight the current knowledge on the regulation of Sost/sclerotin expression and its mechanism(s) of action, discuss novel observations regarding its role in signaling pathways activated by hormones and mechanical stimuli in bone, and propose future research needed to understand the full potential of therapeutic interventions that modulate Sost/sclerostin expression.

AB - After discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency or pharmacological neutralization increases bone formation. Dysregulation of sclerostin expression also underlies the pathophysiology of skeletal disorders characterized by loss of bone mass, as well as the damaging effects of some cancers in bone. Thus, sclerostin has quickly become a promising molecular target for the treatment of osteoporosis and other skeletal diseases, and beneficial skeletal outcomes are observed in animal studies and clinical trials using neutralizing antibodies against sclerostin. However, the anabolic effect of blocking sclerostin decreases with time, bone mass accrual is also accompanied by anti-catabolic effects, and there is bone loss over time after therapy discontinuation. Further, the cellular source of sclerostin in the bone/bone marrow microenvironment under physiological and pathological conditions, the pathways that regulate sclerostin expression and the mechanisms by which sclerostin modulates the activity of osteocytes, osteoblasts, and osteoclasts remain unclear. In this review, we highlight the current knowledge on the regulation of Sost/sclerotin expression and its mechanism(s) of action, discuss novel observations regarding its role in signaling pathways activated by hormones and mechanical stimuli in bone, and propose future research needed to understand the full potential of therapeutic interventions that modulate Sost/sclerostin expression.

KW - Anabolism

KW - Bone formation

KW - Bone resorption

KW - Glucocorticoids

KW - Multiple myeloma

KW - Osteocytes

KW - PTH

KW - Wnt/βcatenin signaling

UR - http://www.scopus.com/inward/record.url?scp=85006132380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006132380&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2016.10.007

DO - 10.1016/j.bone.2016.10.007

M3 - Article

VL - 96

SP - 29

EP - 37

JO - Bone

JF - Bone

SN - 8756-3282

ER -